Division of Medical Oncology, Mayo Clinic, Rochester, MN.
Division of Medical Oncology, Mayo Clinic, Rochester, MN.
Clin Breast Cancer. 2024 Dec;24(8):e757-e763. doi: 10.1016/j.clbc.2024.09.002. Epub 2024 Sep 6.
Eyebrow and eyelash loss, known as madarosis, can occur after breast cancer-directed therapy. The purpose of this study was to ascertain the proportion of breast cancer survivors who experience madarosis, contributing factors, and associations between this symptom and quality of life.
Breast cancer survivors were invited to participate in an ongoing longitudinal cohort study as a part of the Mayo Clinic Breast Disease Registry (MCBDR). Consenting participants were mailed a survey approximately 1 year after diagnosis. The proportions of participants who reported eyebrow and eyelash loss were evaluated overall and according to treatment type. Quality of life (QOL) was also explored in this cohort.
Eight hundred and thirty-eight breast cancer survivors responded to survey. The median age of survivors was 59.4 years (range 22-100 years), 315 (37%) had received chemotherapy (± endocrine therapy), 415 (50%) had received endocrine therapy only. Nearly half of participants reported eyebrow loss (49%) or eyelash loss (49%) that occurred after their diagnosis of breast cancer. Eyebrow loss was reported by 89% of chemotherapy recipients, by 27% of endocrine therapy only recipients, and by 19% of those not treated with either therapy. 102 (32%) of those with chemotherapy-associated eyebrow loss reported that it was complete. Eyelash loss was reported by 274 (87%) of chemotherapy recipients, 112 (27%) of endocrine therapy only recipients, and 23 (21%) of those who received neither therapy.
Madarosis is a common symptom in breast cancer survivors and future investigation into the predictors and treatment of madarosis is needed.
眉毛和睫毛脱落，即眉毛和睫毛缺失，俗称“脱毛症”，可发生于乳腺癌治疗后。本研究旨在确定经历脱毛症的乳腺癌幸存者的比例、相关因素，以及该症状与生活质量之间的关联。
乳腺癌幸存者受邀作为 Mayo 诊所乳腺疾病登记处（MCBDR）的一部分参与一项正在进行的纵向队列研究。在诊断后约 1 年，同意参与的患者会收到一份邮寄的调查问卷。评估了总体以及根据治疗类型报告眉毛和睫毛缺失的参与者比例。该队列还探讨了生活质量（QOL）。
838 名乳腺癌幸存者对调查做出了回应。幸存者的中位年龄为 59.4 岁（范围 22-100 岁），315 名（37%）接受了化疗（±内分泌治疗），415 名（50%）仅接受了内分泌治疗。近一半的参与者报告在诊断乳腺癌后出现了眉毛脱落（49%）或睫毛脱落（49%）。接受化疗的患者中，89%报告眉毛脱落，仅接受内分泌治疗的患者中，27%报告眉毛脱落，而未接受任何治疗的患者中，19%报告眉毛脱落。102 名（32%）接受化疗相关眉毛缺失的患者报告说他们的眉毛完全缺失。接受化疗的患者中，274 名（87%）报告了睫毛脱落，仅接受内分泌治疗的患者中，112 名（27%）报告了睫毛脱落，而未接受任何治疗的患者中，23 名（21%）报告了睫毛脱落。
脱毛症是乳腺癌幸存者的常见症状，需要进一步研究脱毛症的预测因素和治疗方法。
